u/Pale-Shoe3160

The "Therapy Moat" vs. The "Drug-Only" Gamble

When I look at the clinical models for these two companies, the biggest divide isn't just the drug—it’s the cost of the room, and I actually think Compass has the smarter play here.

• The Compass "Support" Model: Compass has been upfront that COMP360 requires "Psychological Support" (a therapist in the room). People call this a burden, but I see it as a Safety Moat. After the FDA rejected Lykos/MDMA in 2024 for not having enough "controlled" oversight, Compass is giving the FDA exactly what they want: a supervised, de-risked environment. It’s the "safe bet" for a first-ever psychedelic approval. 

• The Definium "No Therapy" Bet: Definium is gambling that they can get their LSD tablet (DT-120) approved as a pure pharmaceutical with almost no monitoring. While that sounds cheaper, it’s a massive regulatory risk. If the FDA decides that all psychedelics need supervision—which they’ve hinted at—Definium might have to go back to the drawing board while Compass is already on the market.

When you look under the hood at the TRD vs. MDD battle and the actual timelines for 2026, it’s clear why my position in Compass is strategically different and honestly, a much safer play for a buyout and revenue potential.

• The "MDD is Bigger" Myth: Sure, Major Depressive Disorder (MDD) is a larger total population than Treatment-Resistant Depression (TRD). But in the world of Big Pharma and Insurance, "bigger" doesn’t always mean "easier to monetize."

• The Insurance Barrier: Insurance companies aren't going to shell out $15,000+ for a new, supervised therapy for "regular" depression when they can keep patients on cheap, $10 generic SSRIs. They usually require patients to fail those first.

• The TRD Moat: This is why I like Compass's move to target TRD specifically. These patients have already failed two or more medications, which creates a massive incentive for insurance companies to pay a premium for COMP360 right away.

• The Definium Risk: By comparison, Definium is aiming for MDD, which is a crowded and difficult market. They have to prove they’re better than every cheap pill on the shelf, whereas Compass only has to prove they can help the "unhelpables."